The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis.
Tobias DerfussJaume Sastre-GarrigaX MontalbanM RodegherJ WuerfelLaura GaetanoD TomicA AzmonChristian WolfLudwig KapposPublished in: Multiple sclerosis journal - experimental, translational and clinical (2020)
After 10 years of fingolimod treatment, disability progression was lower in the high-exposure group than in the low-exposure group.
Keyphrases